Authors
Latest:
OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.
Latest:
Emerging Therapeutic for Non-Segmental Vitiligo: Merck’s MK-6194Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.
Latest:
Does diet really play a role in acne?For years, teenagers have been told to avoid certain foods to reduce acne. A review article examines the evidence.
Latest:
An Overview of ArgyriaArgyria is a rare dermatologic condition that presents with blue or grey mucocutaneous discoloration following cutaneous exposure or ingestion of silver.
Latest:
Managing aBCC and aCSCC With Cemiplimab: Tips From Matthew Reynolds, PA-CReynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.
Latest:
Modern Dermatology: Advanced Meds and Social Media MythsRob Casquejo, PA-C, spoke with Dermatology Times on new and upcoming medications, addressing unmet needs, and social media misinformation.
Latest:
Phase 2b Trial Reinforces Zasocitinib’s Safety ProfileMelinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.
Latest:
“Is AI Coming for My Job?”: Familiarizing Clinicians with AI Tools and Their Role in DermatologyIn a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.
Latest:
Telehealth in 2023: What Physicians Need to KnowAnswers to some common questions about providing telehealth services in 2023.
Latest:
Final Thoughts on Tapinarof in AD Clinical TrialsRaj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.
Latest:
Glynis Ablon, MD, Spotlights Top Devices and Innovations in Aesthetic DermatologyAt Fall Clinical 2024, Ablon shared her top device-based interventions, from wound care to radiofrequency rejuvenation, revealing clinical pearls for enhanced aesthetic outcomes.
Latest:
Exploring Advancements in Palmoplantar Pustulosis, Psoriasis Comorbidities, and PhototherapyJoel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.
Latest:
Test Your Knowledge: Acne Pearls From SDPATake this quiz to see if you are leveraging the latest research in acne treatment.
Latest:
OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.
Latest:
Expanding Innovation and Education in Medical AestheticsBob Rhatigan, CEO of Merz Aesthetics, discusses the organization’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.
Latest:
Expert Perspectives on BOLT clinical trial dataJohn Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.
Latest:
Considerations to Best Serve Transgender Patients Seeking Aesthetic CareRonda Farah, MD, and her colleagues reviewed how dermatology providers play an important role in transgender aesthetic care.
Latest:
Patient Education and Novel Topical Therapies for ADPanelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.
Latest:
Beyond Aesthetics: The Vital Role of Nails in HealthMartin Zaiac, MD, gave insight on potential risks associated with manipulation of nails, hygiene, and when it is necessary to see a specialist.
Latest:
Advances and Challenges in Rosacea Treatment: Insights From Hilary Baldwin, MDAt the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted innovative strategies for managing complex rosacea cases, the importance of combination approaches, and a slowing treatment pipeline.
Latest:
Topical Remetinostat Effective, Tolerable in Basal Cell CarcinomaThe topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.
Latest:
Residency Is Ending Soon: Key Financial Tips for Your Next ChapterFrom a financial perspective, the change from resident to attending dermatologist may be profound.
Latest:
Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 3A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.
Latest:
Navigating Challenges and Advancements in Alopecia Areata TreatmentMaryanne Makredes Senna, MD, shares insights into the complexities of treating alopecia areata and guidance for clinicians.
Latest:
Severity of Psoriatic Disease Significantly Associated With Risk of Inflammatory Bowel DiseaseA recent study identified an association between psoriasis severity and IBD, Crohn disease, and ulcerative colitis.
Latest:
Tips for Difficult to Control Chronic Spontaneous UrticariaAmanda L. Michaud, PA-C, shares insights on difficult to control chronic spontaneous urticaria at the ACAAI Annual Scientific Meeting.
